Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Comment by lscfaon May 19, 2021 2:14pm
410 Views
Post# 33231077

RE:Bloom raises target price

RE:Bloom raises target price

Bloom maintains target...  

May 18/21 - We have made adjustments to our forecasts based on Miravo’s 1Q-2021 financial results. Target remains $2.60, and rating remains BUY (Speculative risk). Target price based on average of DCF (12% discount rate) and 5x 2022E adjusted EBITDA. 5x reflects high debt level (C$121.1 MM; 5.0x net debt/equity) – continued deleveraging may justify higher multiples in future periods


lscfa wrote: Mar 2021 - We have updated our forecasts based on 4Q-2020 results and expectation of increased sales and S,G&A as COVID-19 abates and Miravo moves forward with multiple product launches. We are also rolling our valuation model ahead by one year. As a result, our target price increases to $2.60 (was $2.30), and our rating remains BUY (Speculative risk). Target price based on average of DCF (12% discount rate) and 6x 2022E adjusted EBITDA. 6x reflects high debt level: C$126.3 MM; 5.2x net debt/2021E EBITDA) – continued de- leveraging may justify higher multiples in future periods.

 

<< Previous
Bullboard Posts
Next >>